Last reviewed · How we verify
Hydroxyzine HCL
Hydroxyzine is a first-generation antihistamine that blocks H1 receptors to reduce histamine-mediated allergic and anxiety responses.
Hydroxyzine is a first-generation antihistamine that blocks H1 receptors to reduce histamine-mediated allergic and anxiety responses. Used for Pruritus associated with allergic conditions, Anxiety and tension, Urticaria.
At a glance
| Generic name | Hydroxyzine HCL |
|---|---|
| Also known as | Atarax, ATARAX 200 ml syrup,8699624570062,N05BB01, VALIDOL,8699705590019,N05BB01 |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | First-generation H1 antihistamine |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry, Dermatology, Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Hydroxyzine competitively antagonizes H1 histamine receptors on target tissues, reducing itching, urticaria, and other allergic symptoms. It also has anxiolytic properties through central nervous system effects, making it useful for anxiety and tension. The drug crosses the blood-brain barrier and produces sedation as a secondary effect.
Approved indications
- Pruritus associated with allergic conditions
- Anxiety and tension
- Urticaria
Common side effects
- Drowsiness/sedation
- Dry mouth
- Headache
- Dizziness
Key clinical trials
- Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project (PHASE3)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection (PHASE2)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxyzine HCL CI brief — competitive landscape report
- Hydroxyzine HCL updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI